Skip to main content
Top
Published in: Drug Safety 1/2002

01-01-2002 | Current Opinion

Unlicensed and Off-Label Drug Use in Children

Implications for Safety

Authors: Dr Imti Choonara, Sharon Conroy

Published in: Drug Safety | Issue 1/2002

Login to get access

Abstract

A significant number of children receive either an unlicensed or an off-label drug during their stay in hospital. Studies throughout Europe have shown that at least one-third of children in hospital and up to 90% of neonates in a neonatal intensive care unit receive such drug prescriptions. The medicines that are most frequently used off-label include analgesics, antibiotics and bronchodilators. The purpose of licensing a drug is to ensure safety, efficacy and quality. If a drug is used in a different manner, one would expect a greater risk of toxicity. Only three studies have commented on the risk of toxicity in relation to unlicensed or off-label drug use. Only one of these three studies prospectively tried to evaluate the risk associated with off-label and unlicensed drug prescription. This study suggested that the percentage of unlicensed and off-label drug use was significantly associated with the risk of an adverse drug reaction. Two studies looking at adverse drug reactions suggest that there is a greater risk of a severe adverse drug reaction occurring in association with the off-label or unlicensed use of drugs. One study found that five out of eight severe adverse drug reactions were associated with the off-label use of a medicine. The other study found that 14 of 19 drug prescriptions associated with 17 severe adverse drug reactions were either unlicensed or off-label. The risk of prescribing off-label and unlicensed drugs in children is not clear from the limited data available.
Literature
2.
go back to reference Sutherland JM. Fatal cardiovascular collapse of infants receiving large amounts of chloramphenicol. Am J Dis Child 1959: 7 Sutherland JM. Fatal cardiovascular collapse of infants receiving large amounts of chloramphenicol. Am J Dis Child 1959: 7
3.
go back to reference Weiss CF, Glazko AJ, Weston JK. Chloramphenicol in the newborn infant. N Engl J Med 1960; 262: 787–94PubMedCrossRef Weiss CF, Glazko AJ, Weston JK. Chloramphenicol in the newborn infant. N Engl J Med 1960; 262: 787–94PubMedCrossRef
6.
go back to reference Turner S, Nunn AJ, Choonara I. Unlicensed drug use in children in the U.K. Paed Perinatal Drug Ther 1997; 1: 52–5 Turner S, Nunn AJ, Choonara I. Unlicensed drug use in children in the U.K. Paed Perinatal Drug Ther 1997; 1: 52–5
7.
go back to reference Turner S, Gill A, Nunn T, et al. Use of ‘off-label’and unlicensed drugs in paediatric intensive care unit. Lancet 1996; 347: 549–50PubMedCrossRef Turner S, Gill A, Nunn T, et al. Use of ‘off-label’and unlicensed drugs in paediatric intensive care unit. Lancet 1996; 347: 549–50PubMedCrossRef
8.
go back to reference McKinzie JP, Wright SW, Wrenn KD. Pediatric drug therapy in the emergency department; does it meet FDA-approved prescribing guidelines? Am J Emerg Med 1997; 15: 118–21PubMedCrossRef McKinzie JP, Wright SW, Wrenn KD. Pediatric drug therapy in the emergency department; does it meet FDA-approved prescribing guidelines? Am J Emerg Med 1997; 15: 118–21PubMedCrossRef
9.
go back to reference Turner S, Longworth A, Nunn AJ, et al. Unlicensed drug use on paediatric wards. BMJ 1998; 316: 343–5PubMedCrossRef Turner S, Longworth A, Nunn AJ, et al. Unlicensed drug use on paediatric wards. BMJ 1998; 316: 343–5PubMedCrossRef
10.
go back to reference Turner S, Nunn AJ, Fielding K, et al. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr 1999; 88: 965–8PubMedCrossRef Turner S, Nunn AJ, Fielding K, et al. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr 1999; 88: 965–8PubMedCrossRef
11.
go back to reference Turner S. Unregistered and off-label drug use in paediatric inpatients. Aust J Hosp Pharm 1999; 29: 265–8 Turner S. Unregistered and off-label drug use in paediatric inpatients. Aust J Hosp Pharm 1999; 29: 265–8
12.
go back to reference Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off-label drug use in paediatric wards in European countries. BMJ 2000; 320: 79–82PubMedCrossRef Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off-label drug use in paediatric wards in European countries. BMJ 2000; 320: 79–82PubMedCrossRef
13.
go back to reference Conroy S, McIntyre J, Choonara I. Unlicensed and off label drug use in neonates. Arch Dis Child Fetal Neonatal Ed 1999; 80: F142–5PubMedCrossRef Conroy S, McIntyre J, Choonara I. Unlicensed and off label drug use in neonates. Arch Dis Child Fetal Neonatal Ed 1999; 80: F142–5PubMedCrossRef
14.
go back to reference Wilton LV, Pearce G, Mann RD. The use of newly marketed drugs in children and adolescents prescribed in general practice. Pharmacoepidemiol Drug Saf 1999; 8: S37–45PubMedCrossRef Wilton LV, Pearce G, Mann RD. The use of newly marketed drugs in children and adolescents prescribed in general practice. Pharmacoepidemiol Drug Saf 1999; 8: S37–45PubMedCrossRef
15.
go back to reference McIntyre J, Conroy S, Avery A, et al. Unlicensed and off label prescribing of drugs in general practice. Arch Dis Child 2000; 83: 498–501PubMedCrossRef McIntyre J, Conroy S, Avery A, et al. Unlicensed and off label prescribing of drugs in general practice. Arch Dis Child 2000; 83: 498–501PubMedCrossRef
16.
go back to reference Chalumeau M, Treluyer JM, Salanave B, et al. Off label and unlicensed drug use among French office based paediatricians. Arch Dis Child 2000; 83: 502–5PubMedCrossRef Chalumeau M, Treluyer JM, Salanave B, et al. Off label and unlicensed drug use among French office based paediatricians. Arch Dis Child 2000; 83: 502–5PubMedCrossRef
17.
go back to reference Jong GW, Vulto AG, de Hoog M, et al. Unapproved and off-label use of drugs in a children’s hospital. N Engl J Med 2000; 343: 1125PubMedCrossRef Jong GW, Vulto AG, de Hoog M, et al. Unapproved and off-label use of drugs in a children’s hospital. N Engl J Med 2000; 343: 1125PubMedCrossRef
18.
go back to reference Impicciatore P, Choonara I. Status of new medicines approved by the European Medicines Evaluation Agency regarding paediatric use. Br J Clin Pharmacol 1999; 48: 15–8PubMedCrossRef Impicciatore P, Choonara I. Status of new medicines approved by the European Medicines Evaluation Agency regarding paediatric use. Br J Clin Pharmacol 1999; 48: 15–8PubMedCrossRef
19.
go back to reference Impicciatore P, Choonara I, Clarkson A, et al. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol 2001; 52: 77–83PubMedCrossRef Impicciatore P, Choonara I, Clarkson A, et al. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol 2001; 52: 77–83PubMedCrossRef
20.
go back to reference Gill AM, Leach HJ, Hughes J, et al. Adverse drug reactions in a paediatric intensive care unit. Acta Paediatr 1995; 84: 438–41PubMedCrossRef Gill AM, Leach HJ, Hughes J, et al. Adverse drug reactions in a paediatric intensive care unit. Acta Paediatr 1995; 84: 438–41PubMedCrossRef
21.
go back to reference Clarkson A, Ingleby E, Choonara I, et al. A novel scheme for the reporting of adverse drug reactions. Arch Dis Child 2001; 84: 337–9PubMedCrossRef Clarkson A, Ingleby E, Choonara I, et al. A novel scheme for the reporting of adverse drug reactions. Arch Dis Child 2001; 84: 337–9PubMedCrossRef
22.
go back to reference Hughes J, Leach HJ, Choonara I. Hallucinations on withdrawal of isoflurane used as sedation. Acta Paediatr 1993; 82: 885–6PubMed Hughes J, Leach HJ, Choonara I. Hallucinations on withdrawal of isoflurane used as sedation. Acta Paediatr 1993; 82: 885–6PubMed
Metadata
Title
Unlicensed and Off-Label Drug Use in Children
Implications for Safety
Authors
Dr Imti Choonara
Sharon Conroy
Publication date
01-01-2002
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 1/2002
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200225010-00001

Other articles of this Issue 1/2002

Drug Safety 1/2002 Go to the issue